Latest Earnings Results: Q4 '26
Estimated EPS
$0.20
Reported EPS
---
Surprise
---
Estimated Rev
$125.2M
Reported Rev
$111.6M
Surprise
-10.86%
• Reported GAAP EPS of -$0.24 down -700.00% YoY • Reported revenue of $111.6M down -2.02% YoY • Alvotech maintains full-year 2026 guidance for total revenue of $650M and EBITDA of $180M, with performance now expected toward the lower end of the range.
Bullish Takeaway
Alvotech reported FDA acceptance of AVT80's BLA and a first-known worldwide Eylea HD submission, approval of a Simlandi process more than doubling batch output, and Lotus commercialization rights.
Bearish Takeaway
Alvotech's nine-month adjusted revenue and gross margin were lower than the same period last year; full-year performance is expected toward guidance's lower end, and production and commercial supply continue ramping for planned fourth-quarter deliveries.
Generated by Stocktwits using AI and company-reported earnings data for Q4 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | $0.20 | -- | -- | N/A |
Q3 '26 | -$0.04 | -- | -- | N/A |
Q2 '26 | -$0.05 | -- | -- | N/A |
Q1 '26 | -$0.05 | -$0.09 | -91.50% | MISSED |
Q4 '25 | -$0.01 | -- | -- | N/A |